

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


| | | | |
|-------------|------------------------------------|---|----------------------|
| Applicant: | XU, Yuelian, et al. |) | Group Art Unit: 1624 |
| | |) | |
| Serial No.: | NYA |) | Examiner: Jeffrey H. |
| | |) | MURRAY |
| Filed: | October 19, 2005 |) | |
| | |) | |
| For: | SUBSTITUTED IMIDAZOLOPYRAZINE AND |) | |
| | TRIAZOLOPYRAZINE DERIVATIVES: |) | |
| | GABA _A RECEPTOR LIGANDS |) | |

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This Response is submitted in view of the Restriction Requirement dated April 3, 2008. Applicants elect Group III in which Z₁ and Z₂ are N and Z₃ is CR₃, with traverse. Applicants request rejoinder of Group IV in which Z₁ and Z₃ are N and Z₂ is CR₂. Applicants also traverse the Examiner's limitation of R₅ to a single group, propyl. In view of the requirement that Applicants elect a single disclosed species within Group III, Applicants hereby elect the compound of Example 6, 5-propyl-6-(2-pyridin-2-yl-imidazol-1-ylmethyl)-[1,2,4] triazolo[4,3-a]pyrazine



Prior to examination, please amend the application as follows:

Amendments to the Claims begin on Page 2 of this paper.

Remarks begin on Page 6 of this paper.